Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials

During the past decades, agents with novel mechanisms of action, such as monoclonal antibodies (MAbs) and histone deacetylase inhibitors (HDACis) have been applied to treat relapsed or refractory multiple myeloma (RRMM). The treatment outcomes of MAbs versus HDACi in combination with bortezomib or l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yanhua, Shen, Hongyuan, Xu, Li, Feng, Juan, Tang, Hailong, Zhang, Na, Chen, Xiequn, Gao, Guangxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040277/
https://www.ncbi.nlm.nih.gov/pubmed/30050957
http://dx.doi.org/10.1155/2018/7646913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040277/
https://www.ncbi.nlm.nih.gov/pubmed/30050957
http://dx.doi.org/10.1155/2018/7646913

Ejemplares similares